Nupur Ghoshal

Professor

Washington University in St. Louis
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

Importance Neurofilament light (NfL) is elevated in CSF and blood across a range of traumatic, inflammatory and neurodegenerative diseases of the central nervous system, and has been increasingly included in clinical trials as an outcome measure of target engagement. Interpreting trajectories of NfL post-treatment has been challenging, prompting a greater need and focus on understanding its pathophysiology. Objective We measured NfL kinetics in the human central nervous system using stable isotope labeling kinetics (SILK). Design Observational study. Participants underwent SILK protocol. Infusion of 16 hours with 4mg/kg/h and follow-up lumbar punctures scheduled at 7, 14, 60 and 120 days post-labeling. Setting Referral center – specialist neurology clinic. Participants Participants with diagnosed primary tauopathies (n=10) were recruited to the Human CNS Tau Kinetics in Tauopathies (TANGLES) study. A control case was examined post-mortem to assess the technical background of the SILK method. Exposure Intravenous infusion of 13 C 6 -leucine, with rates of label incorporation representative of fractional synthesis and fractional clearance rates in vivo and in vitro . Main outcome and Measure Level of incorporation of 13 C 6 -leucine tracer into newly-translated NfL divided by the pool of NfL with previously incorporated 12 C 6 -leucine, expressed as a percentage tracer-to-tracee (TTR) ratio. Results NfL is rapidly translated in human brain within hours but takes 53 – 162 days to appear in cerebrospinal fluid (CSF). Labeled NfL remains detectable in post-mortem brain tissue 1.5 years post-labeling, indicating an extremely slow turnover in the human CNS. Together, these data suggest the greatest contribution of CSF NfL in neurodegeneration is from slow release of a large pool of previously translated NfL. However, release of newly translated NfL makes a significant contribution. Conclusion and relevance Rapid increases in CSF NfL seen within weeks of disease processes or interventions are likely to reflect release of pre-existing NfL from damaged neurons, but later increases in NfL (>3 months) may also reflect new NfL translation and release. Clinical trials using NfL as an outcome measure to track neurodegeneration would particularly benefit from substantially longer follow-up periods due to the slow turnover of the protein in the central nervous system.

Year:

2025

Objectives Hyperorality is one of the core features of behavioral variant frontotemporal dementia (bvFTD), however, the cognitive, psychiatric, and neuroanatomic correlates of hyperorality across disease stages remain unclear. This study works to fill this knowledge gap by exploring these associations in the early and advanced stages of bvFTD. Methods Participants with sporadic and genetic bvFTD were enrolled in the ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration consortium (ALLFTD). The primary analyses used baseline data to compare cognitive and psychiatric symptoms in those with and without hyperorality stratified by disease severity. Linear multivariable regressions adjusting for age and total intracranial volume were used to examine baseline associations between regional gray matter volumes and hyperorality status. Five anatomic regions of interest were pre-selected for analysis based on previously identified neuroanatomic correlates of hyperorality in bvFTD. Results Hyperorality was present in 50% of early-stage bvFTD participants (n = 136) and was associated with higher rates of ritualistic/compulsive behavior. Hyperorality was present in 63% of advanced-stage participants (n = 208) and was associated higher rates of apathy, and ritualistic/compulsive behavior. Regional gray matter volumes were similar in those with and without hyperorality in early-stage participants. In the advanced-stage participants, hyperorality was associated with lower gray matter volumes in the right dorsal and ventral striatum. Conclusions Hyperorality emerges early in bvFTD and is accompanied by deficits in social cognition and complex-ritualistic behavior prior to clinically significant gray matter volume loss. These findings suggest that early identification and treatment of hyperorality could improve neuropsychiatric trajectories in bvFTD.

Year:

2024

Dementia is characterized by a decline in memory and thinking that is significant enough to impair function in activities of daily living. Patients seen in dementia specialty clinics are highly heterogenous with a variety of different symptoms that progress at different rates. Recent research has focused on finding data-driven subtypes for revealing new insights into dementia’s underlying heterogeneity, compared to analyzing the entire cohort as a single homogeneous group. However, current studies on dementia subtyping have the following limitations: (i) focusing on AD-related dementia only and not examining heterogeneity within dementia as a whole, (ii) using only cross-sectional baseline visit information for clustering and (iii) predominantly relying on expensive imaging biomarkers as features for clustering. In this study, we seek to overcome such limitations, using a data-driven unsupervised clustering algorithm named SillyPutty, in combination with hierarchical clustering on cognitive assessment scores to estimate subtypes within a real-world clinical dementia cohort. We use a longitudinal patient data set for our clustering analysis, instead of relying only on baseline visits, allowing us to explore the ongoing temporal relationship between subtypes and disease progression over time. Results showed that subtypes with very mild or mild dementia were more heterogenous in their cognitive profiles and risk of disease progression.

Year:

2024

The pathophysiological mechanisms driving disease progression of frontotemporal lobar degeneration (FTLD) and corresponding biomarkers are not fully understood. We leveraged aptamer-based proteomics (> 4,000 proteins) to identify dysregulated communities of co-expressed cerebrospinal fluid proteins in 116 adults carrying autosomal dominant FTLD mutations ( C9orf72 , GRN , MAPT ) compared to 39 noncarrier controls. Network analysis identified 31 protein co-expression modules. Proteomic signatures of genetic FTLD clinical severity included increased abundance of RNA splicing (particularly in C9orf72 and GRN ) and extracellular matrix (particularly in MAPT ) modules, as well as decreased abundance of synaptic/neuronal and autophagy modules. The generalizability of genetic FTLD proteomic signatures was tested and confirmed in independent cohorts of 1) sporadic progressive supranuclear palsy-Richardson syndrome and 2) frontotemporal dementia spectrum syndromes. Network-based proteomics hold promise for identifying replicable molecular pathways in adults living with FTLD. ‘Hub’ proteins driving co-expression of affected modules warrant further attention as candidate biomarkers and therapeutic targets.

Year:

2024

Collaborators (27)

Doug Galasko

UC San Diego Health System

UNITED STATES
View details

Lawrence Honig

Professor, Director of NYS Center of Excellence for Alzheimer's Disease, Deputy Director Alzheimer's Disease Research Center

Columbia University Irving Medical Center

UNITED STATES
View details

Maria Carmela Tartaglia

University of Toronto

CANADA
View details

Chiadi Onyike

Associate Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Nicholas Seyfried

Professor

Emory University

UNITED STATES
View details

Suzanne Schindler

Associate Professor

Washington University in St. Louis

UNITED STATES
View details

Ging-Yuek Hsiung

The University of British Columbia

CANADA
View details

Alexander Pantelyat

Associate Professor

Johns Hopkins University

UNITED STATES
View details

Erik Roberson

University of Alabama, Tuscaloosa

UNITED STATES
View details

Oskar Hansson

Full professor of Neurology

Lund University

SWEDEN
View details

Daniel H. Geschwind

University of California

UNITED STATES
View details

Erik Johnson

Assistant Professor

Emory University School of Medicine

UNITED STATES
View details

Gregory Day

Associate Professor, Consultant

Mayo Clinic

UNITED STATES
View details

Jennifer Yokoyama

University of California

UNITED STATES
View details

Christopher Morrow

Johns Hopkins University School of Medicine

UNITED STATES
View details

Eric Dammer

Scientist, Bioinformatics

Emory University

UNITED STATES
View details

Randall Bateman

Washington University in St. Louis

UNITED STATES
View details

Andreia Faria

earth and planetary sciences johns hopkins university baltimore maryland usa

UNITED STATES
View details

Irene Litvan

Professor

University of California, San Diego

UNITED STATES
View details

Philip Payne

Janet and Bernard Becker Professor and Director

Washington University in St. Louis

UNITED STATES
View details

Mario Mendez

Professor

University of California, Los Angeles

UNITED STATES
View details

Neill Graff-Radford

Professor

Mayo Clinic Florida

UNITED STATES
View details

Lea T. Grinberg

-

UNITED STATES
View details

Allison Snyder

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Tatiana Alvarez Giovannucci

Karolinska Institutet

SWEDEN
View details

Salvatore Spina

Associate Professor

University of California, San Francisco

UNITED STATES
View details

Adam M. Staffaroni

University of California

UNITED STATES
View details